The invention relates to novel liquid pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more polar organic solvents, wherein the at least one SGLT-2 inhibitor comprises 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene according to formula (I):as well as corresponding processes of manufacturing such liquid pharmaceutical compositions and their medical uses.本發明係關於新穎液態醫藥組合物,其包含至少一種SGLT-2抑制劑及一或多種極性有機溶劑,其中該至少一種SGLT-2抑制劑包含根據式(I)之1-氰基-2-(4-環丙基-苄基)-4-(β-D-吡喃葡萄糖-1-基)-苯:以及製造該等液態醫藥組合物之相應方法及其醫療用途。